Dovre Q4 results topped our estimates due to Project Personnel.
Redeye updates its view of Egetis following the Q4 report and recent events in the company.
Scanfil’s Q4 top line developed flat as expected, while the EUR 13.
Dovre’s Q4 results came in above our estimates thanks to Project Personnel, while Consulting and Ren...
Redeye saw a sales development that was a bit softer than expected.
Redeye states that the report was below expectations on sales and profitability.
Adj. EBITDA ~60% below ABGSCe ACV growth of 3% q-o-q Negative consensus estimate revisions likely Q...
NOI increased 20% y-o-y, +2% vs. ABGSCe Value changes -0.
Net sales, EPS and dividend proposal were in line with consensus (LSEG) in Q4 but EBIT margin was be...
Redeye updates on Better Collective following its Q4-results where the outcome was in line with the ...
Redeye provides an update on Thunderful Group following its Q4 2023 report, which showed weak number...
Redeye comments on Lipigons fourth quarter report. We discuss Lipigon's phase II study, other projec...
Redeye reviews BioInvent’s fourth quarter. The company now has six active clinical programs with sev...
Redeye states the report aligned with its sales estimates.
A weak market environment and weak cargo tonnes have taken the share price to an all-time low in Feb...
Ahead of Cibus' Q4 2023 report, we leave our operational estimates largely unchanged, while we raise...
Atria's Q4 adjusted EBIT of EUR 9.4m fell clearly short of LSEG Data & Analytics consensus expectati...
High costs in Germany to be scaled down, strong results in the US German downgrades outweigh US upgr...
First Venture publicerade den 22 februari 2024 bolagets delårsrapport för det fjärde kvartalet av 20...
Arctic Blue Beverages AB (”Arctic Blue Beverages” eller ”Bolaget”) redovisar en markant minskad nett...
